Spark Newswire Spark Newswire
  • Newswire
  • News
    • Guidance
    • Dividends
    • M&A
    • Buybacks
    • Legal
    • Interviews
    • Management
    • Offerings
    • IPOs
    • Insider Trades
    • Biotech/FDA
    • Tech
  • Markets
    • After Hours
    • Movers
    • ETFs
    • Forex
    • Commodities
    • Options
    • Binary Options
    • Bonds
    • Futures
    • Global Economics
    • Reviews
    • Small-Cap
    • Cryptocurrency
    • Penny Stocks
  • Analysts
    • Analyst Color
    • Analyst Ratings
    • Upgrades
    • Downgrades
  • Earnings
    • Earnings
  • Support & Feedback
  • Registration Options
  • Log In
News by Category
  • After-Hours Center
  • Analyst Color
  • Analyst Ratings
  • Asia
  • Asset Sales
  • Binary Options
  • Biotech
  • Bonds
  • Broad U.S. Equity ETFs
  • Buybacks
  • Cannabis
  • Commodities
  • Contracts
  • Crowdsourcing
  • Cryptocurrency
  • Currency ETFs
  • Dividends
  • Downgrades
  • Earnings
  • Earnings Beats
  • Earnings Misses
  • Econ #s
  • Economics
  • Education
  • Emerging Market ETFs
  • Emerging Markets
  • Entertainment
  • Entrepreneurship
  • Equities
  • ESG
  • ETFs
  • Eurozone
  • Events
  • Exclusives
  • FDA
  • Federal Reserve
  • Financial Advisors
  • Financing
  • Fintech
  • Forex
  • Futures
  • Gaming
  • General
  • Global
  • Government
  • Guidance
  • Health Care
  • Hedge Funds
  • Hot
  • Initiation
  • Insider Trades
  • Insurance
  • Interview
  • Intraday Update
  • IPOs
  • Large Cap
  • Latin America
  • Legal
  • Long Ideas
  • M&A
  • Macro Economic Events
  • Macro Notification
  • Management
  • Market Summary
  • Market-Moving Exclusives
  • Markets
  • Media
  • Mid Cap
  • Movers
  • Movers & Shakers
  • Mutual Funds
  • New ETFs
  • News
  • Offerings
  • Opinion
  • Options
  • Penny Stocks
  • Personal Finance
  • Politics
  • Pre-Market Outlook
  • Press Releases
  • Previews
  • Price Target
  • Psychedelics
  • Psychology
  • Real Estate
  • Regulations
  • REIT
  • Reiteration
  • Restaurants
  • Retail Sales
  • Reviews
  • Rumors
  • SEC
  • Sector ETFs
  • Short Ideas
  • Short Sellers
  • Signals
  • Small Business
  • Small Cap
  • Small Cap Analysis
  • Small-Cap
  • Social Media
  • SPACE
  • Specialty ETFs
  • Sports
  • Sports Betting
  • Startups
  • Stock Split
  • Success Stories
  • Tech
  • Technicals
  • Termination
  • Top Stories
  • Topics
  • Trading Ideas
  • Travel
  • Treasuries
  • Uncategorized
  • Upgrades
Spark Newswire Spark Newswire
Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.
  • Newswire
  • News
    • Guidance
    • Dividends
    • M&A
    • Buybacks
    • Legal
    • Interviews
    • Management
    • Offerings
    • IPOs
    • Insider Trades
    • Biotech/FDA
    • Tech
  • Markets
    • After Hours
    • Movers
    • ETFs
    • Forex
    • Commodities
    • Options
    • Binary Options
    • Bonds
    • Futures
    • Global Economics
    • Reviews
    • Small-Cap
    • Cryptocurrency
    • Penny Stocks
  • Analysts
    • Analyst Color
    • Analyst Ratings
    • Upgrades
    • Downgrades
  • Earnings
    • Earnings
  • Support & Feedback
  • Registration Options
  • Log In
Spark Newswire Spark Newswire
Filter By Ticker
Search By Date To
Today | Yesterday | This week

Latest news

Group By Ticker
Sort By
Newest | Oldest
Read More
1 minute read
  • Biotech
  • General
  • Health Care
  • Movers
  • News
  • Penny Stocks
  • Small Cap
  • Trading Ideas

Amarin Posts Encouraging Vascepa Data In Patients With Peripheral Artery Disease

By Vandana Singh
November 16, 12:35 PM
Amarin Corporation plc (NASDAQ:AMRN) reported new data for Vascepa/Vazkepa (icosapent ethyl) at the American Heart Association (AHA) Scientific Sessions. The investigators…

AMRN

Read More
1 minute read
  • M&A
  • News
  • Rumors

Watching Amarin Shares; DealReporter Says Activist Investor May Be Pushing For Sale

By Benzinga Newsdesk
November 16, 11:28 AM
-Financial Times' DealReporter

AMRN

Read More
4 minute read
  • Biotech
  • Earnings
  • FDA
  • News
  • Penny Stocks
  • Small Cap
  • Top Stories

The Week Ahead In Biotech (Nov. 14-Nov. 20): BioMarin FDA Decision, Tapering Earnings News Flow, Conference Presentations And More

By Shanthi Rexaline
November 14, 10:57 AM
Biotech stocks declined for the second straight week amid a broader market pullback, along with earnings news from small- and micro-cap companies and presentations at multiple conferences.

ACRX

Read More
2 minute read
  • Earnings

Amarin Corp Earnings Perspective: Return On Capital Employed

By Benzinga Insights
November 3, 12:01 PM
Amarin Corp (NASDAQ:AMRN) brought in sales totaling $142.04 million during Q3 according to data provided by Benzinga Pro. However, earnings decreased 249.01%, resulting in a loss of $13.07 million.

AMRN

Read More
1 minute read
  • Earnings
  • News

Amarin Corp Q3 EPS $0.03 Beats $(0.03) Estimate, Sales $142.04M Miss $161.96M Estimate

By Bill Haddad
November 3, 6:08 AM
Amarin Corp (NASDAQ:AMRN) reported quarterly earnings of $0.03 per share which beat the analyst consensus estimate of $(0.03) by 200 percent. This is a 250 percent increase over losses of $(0.02) per share from the same

AMRN

Read More
25 minute read
  • Earnings
  • Markets
  • News
  • Pre-Market Outlook

Earnings Scheduled For November 3, 2021

By Benzinga Insights
November 3, 3:43 AM
  Companies Reporting Before The Bell • R.R.Donnelley & Sons (NYSE:RRD) is likely to report quarterly earnings at $0.32 per share on revenue of $1.19 billion.

AAWW

Read More
7 minute read
  • Biotech
  • Earnings
  • FDA
  • IPOs
  • News
  • Penny Stocks
  • Small Cap
  • Top Stories

The Week Ahead In Biotech (Oct. 31-Nov. 6): Earnings Pick Up Pace, Eton Awaits Seizure Drug Approval, Kidney Conference, More IPOs In The Pipeline

By Shanthi Rexaline
October 31, 2:23 PM
Biotech stocks rose a third week running in the week ending Oct. 29 amid positive reaction to earnings. Big pharma earnings were mostly better than expected.

ADPT

Read More
1 minute read
  • Media

Cramer Shares His Thoughts On Dynavax, Nucor And Amarin

By Craig Jones
September 24, 8:05 AM
On CNBC's "Mad Money Lightning Round," Jim Cramer said Dynavax Technologies Corporation (NASDAQ: DVAX) is good. He loves the immuno drug stories.

AMRN

Read More
3 minute read
  • News

Amarin Outlines New Go-To-Market Strategy To Accelerate VASCEPA Growth In US

By Benzinga Newsdesk
September 22, 9:15 AM
Amarin Corporation plc (NASDAQ:AMRN) today outlined its new Go-to-Market strategy to accelerate growth of VASCEPA® (icosapent ethyl) in the United States, which focuses on expanding healthcare professional engagement

AMRN

Read More
11 minute read
  • Penny Stocks

TENX: Second Quarter Results

By Zacks Small Cap Research
September 20, 2:43 PM
By John Vandermosten, CFA NASDAQ:TENX READ THE FULL TENX RESEARCH REPORT

AMRN

Posts navigation

Previous 1 … 5 6 7 … 9 Next
Free Newsletter subscribe

Stock Market Ideas & Analysis

Stay up-to-date with the same information professionals use.
Spark Newswire Spark Newswire
  • Newswire
  • Registration
  • Log In
  • Settings
  • Privacy Policy
  • Terms of Service
© 2021 Spark Newswire
All Rights Reserved.

All news is property of their respective owners. Terms of Service